



January 22, 2022

To,  
The Manager  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (East), Mumbai - 400 051

**Stock Code: VAISHALI**

**Sub: Publication in the Newspaper of Un-Audited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2021.**

Dear Sir / Madam,

Pursuant to Regulation 47 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of the newspaper publication in respect of Un-Audited Standalone Financial Results of the Company for the Quarter and Nine Months Ended December 31, 2021 published in the following newspapers on January 22, 2022:-

1. Financial Express;
2. Pratahkal.

Kindly take the above on records.

Thanking you

Yours faithfully,  
**For Vaishali Pharma Limited**

*Vishwa*



Vishwa Mekhia  
Company Secretary & Compliance Officer

**BNP PARIBAS MUTUAL FUND**  
 Investment Manager: BNP Paribas Asset Management India Private Limited (AMC)  
 Corporate Identity Number (CIN): U05999MH2002PTC142972  
 Registered Office: Crescendo, 7<sup>th</sup> Floor, G-Block, Bandra Kurla Complex, Bandra - East, Mumbai - 400 051.  
 Website: www.bnpparibas.in | Toll Free: 1800 102 2595

**NOTICE CUM ADDENDUM NO. 03/2022**  
 Declaration of Income Distribution cum Capital Withdrawal (IDCW) under the designated Scheme of BNP Paribas Mutual Fund (the Fund).  
 Notice is hereby given that the Trustees of the Fund have approved distribution under Income Distribution cum Capital Withdrawal ("IDCW") Options of the following Schemes at the stated rate per unit subject to available distributable surplus and (w.e.f. Thursday, January 27, 2022) as the Record Date.

Name of the Scheme	Name of the Plan/Option	NAV per unit as on January 20, 2022 (Face value per unit of ₹ 10/-)	Distribution per unit ** (₹)
BNP Paribas Multi Cap Fund	IDCW Option	20.771	0.07
	Direct Plan - IDCW Option	24.971	0.07
BNP Paribas Substantial Equity Hybrid Fund	Regular Plan - IDCW Option	15.9378	0.07
	Direct Plan - IDCW Option	17.1495	0.07

\* For the immediately following Business Day, if that day is not a Business Day.  
 † The distribution will be subject to the availability of distributable surplus and may be lower, depending on the distributable surplus available on the Record Date.  
 \*\* Net distribution amount will be paid to the unit holders under respective categories after deducting applicable taxes, if any.  
 For the units held in physical form, amount of distribution will be paid to all unit holders whose names appear in the records of the Registrar at the close of business hours on the record date and for units held in demat form, the names appearing in the beneficial owners master with the Depository as on the record date shall be considered.

Pursuant to distribution under IDCW, NAV of the IDCW option of the scheme(s) would fall to the extent of payout and statutory levy (if applicable).  
 For BNP Paribas Asset Management India Private Limited  
 Investment Manager to BNP Paribas Mutual Fund

Sd/-  
 Authorised Signatory  
 Date: January 21, 2022  
 Place: Mumbai

**MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.**

**LIC Mutual Fund**  
 LIC Mutual Fund Asset Management Limited  
 (Investment Managers to LIC Mutual Fund)  
 CIN No: L67103MH1997PC207358  
 Registered Office: Industrial Assurance Bldg, 4<sup>th</sup> Floor, Cnp, Chhatrapati Station, Mumbai - 400 002  
 Tel. No.: 022-66016000, Toll Free No.: 1800 256 5678, Fax No.: 022-22835606  
 Email: service@licmf.com | Website: www.licmf.com

**NOTICE-CUM-ADDENDUM No. 47 of 2021-2022**  
 Declaration of Income Distribution cum Capital Withdrawal (IDCW) under below Scheme of LIC Mutual Fund:-  
 NOTICE is hereby given that LIC Mutual Fund Trustee Private Limited, the Trustee to LIC Mutual Fund, has approved the following:-

Name of the Scheme	Face Value (₹ per unit)	IDCW Rate (₹ per unit) *	Record Date **	NAV as on 20/01/2022 (₹ per unit)
LIC MF Equity Hybrid Fund - Direct Plan IDCW Option	10.00	0.10	27 <sup>th</sup> January 2022	17.3663
LIC MF Equity Hybrid Fund - Regular Plan IDCW Option	10.00	0.10	27 <sup>th</sup> January 2022	15.441

\* The payout shall be subject to tax deducted at source (TDS) as applicable.  
 \*\* Or the immediate next Business Day, if that day is not a Business Day.  
 Pursuant to payment of IDCW, the NAV of the IDCW Option(s) of the scheme would fall to the extent of payout and statutory levy.  
 Income distribution is subject to the availability of distributable surplus, will be paid, net of TDS, as applicable, to those Unit holders whose names appear in the Register of Unit holders / Statement of Beneficial owners (as applicable) under the IDCW Option(s) of the aforesaid scheme as on the Record Date.  
 With regard to Unit holders under the IDCW Option of the scheme, who have opted for reinvestment of Income Distribution cum Capital Withdrawal, the IDCW due will be reinvested net of TDS, as applicable, by allotting Units for the income distribution amount at the prevailing ex-IDCW NAV per Unit on the Record Date.

**For LIC Mutual Fund ASSET MANAGEMENT LIMITED**  
 Date: 21/01/2022  
 Place: Mumbai  
 Sd/-  
 Authorized Signatory  
 As part of Go-Green initiative, investors are encouraged to register/update their email ID and Mobile Number with us to support paper-less communication.  
 Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

**GUJARAT STATE ELECTRICITY CORPORATION LIMITED**  
 REGD & ADMIN OFFICE: Vignesh Bhawan, Bani Chaurse, Yashodra-300807, Ph. (025) - 4612131/65132/6612141, Fax: (025) - 2541580  
 URL: www.gseb.com, www.gsecl.com

**Tender No. GSECL/ PPI/ PPI/ FGD / New Units / Ph-II/49**  
 The Chief Engineer (P&P), Gujarat State Electricity Corporation Limited, Vignesh Bhawan, Bani Chaurse, Yashodra-300807, Gujarat, invites tender for "Supply, installation, commissioning & testing of FGD system for 500 MW Unit No. 6 at UKI TPS and 2x250 MW Unit No. 3 & 4 of Sikka TPS with comprehensive O&M contract".  
 Tender Documents & Specifications may be downloaded from Website <http://gsecl.gsecl.com> (For view, download and on-line submission) from 26.01.2022 onwards. Bidder can view & download IES (Notice Inviting Bid) & ITB (Instruction to Bidders) on GUVNL/ GSECL website [www.guvnl.com](http://www.guvnl.com) & [www.gsecl.com](http://www.gsecl.com).  
 Note: Be remain updated with above Websites for any notices/amendments/clarifications etc. till opening of Tender.  
 Chief Engineer (P&P), Gujarat State Electricity Corporation Limited

**FORM G**  
 INVITATION FOR EXPRESSION OF INTEREST  
 (Under Regulation 36A (1) of the Insolvency and Bankruptcy (Insolvency) Resolution Process for Corporate Persons) Regulations, 2016

Sl. No.	RELEVANT PARTICULARS	Details
1	Name of the corporate debtor	<b>INDIRA INDUSTRIES LIMITED</b>
2	Date of incorporation of corporate debtor	10/11/1986
3	Authority under which corporate debtor is incorporated / registered	Registrar of Companies (ROC), Mumbai - 400002 Maharashtra
4	Corporate identity number / limited liability identification number of corporate debtor	L99999MH1986PLC000201
5	Address of the registered office and principal office (if any) of corporate debtor	Registered Office: Plot No. 609-4th Floor, 114 G.D. Nalwar Chk. 15, Shantadurga Gurdhary Marg, Kharadi Mumbai - 400022 Maharashtra Corporate Office & Works: Ram Mandir Ward, Tal. Hinglajhat, Dist. Wardha, -442301, Maharashtra
6	Insolvency commencement date of the corporate debtor	30 <sup>th</sup> August, 2021 (IECL Mumbai Bench passed order dated 30.08.2021 in CP (IB)-68/MB/2020 and Copy of the order was made available to the SIP on 09th November, 2021 & the exclusion period of 70 days had been filed with ICLT)
7	Date of initiation of expression of interest	22/12/2021
8	Eligibility for resolution applicants under section 25(2)(b) of the Code is available at	Website can be sought by emailing at <a href="mailto:camg99@gmail.com">camg99@gmail.com</a> & <a href="mailto:corp.mumbai@gmail.com">corp.mumbai@gmail.com</a>
9	Forms to be submitted by resolution applicants under section 29A are available at	Website can be sought by emailing at <a href="mailto:camg99@gmail.com">camg99@gmail.com</a> & <a href="mailto:corp.mumbai@gmail.com">corp.mumbai@gmail.com</a>
10	Consent/objection expressions/objections	08/02/2022
11	Date of issue of prospectus to prospective resolution applicants	18/02/2022
12	Last date for submission of objections to provisional list	21/02/2022
13	Date of issue of final list of prospective resolution applicants	03/03/2022
14	Date of issue of information memorandum, evaluation matrix and request for resolution plans to prospective resolution applicants	21/02/2022
15	Website for uploading request for resolution plan, evaluation matrix, submission information and further information	By Email
16	Last date for submission of resolution plans	23/03/2022
17	Website for uploading resolution plans to the resolution professional	By the email address by postmaster or hand delivery to the IP corresponding address mentioned against serial no 21 and also in electronic form on email id <a href="mailto:camg99@gmail.com">camg99@gmail.com</a> & <a href="mailto:corp.mumbai@gmail.com">corp.mumbai@gmail.com</a>
18	Estimated date for submission of resolution plan to the Adjudicating Authority for approval	22/04/2022
19	Name and registration number of the resolution professional	<b>MAHESH KUMAR GUPTA</b> IBBI/PA-001/IP-004782017-0018/10866
20	Name, address and e-mail of the resolution professional, as registered with the Board	<b>MAHESH KUMAR GUPTA</b> C/O KEMCO & Associates Office at 202, New Heera Parva Industrial Estate, Near Vignesh Industrial Estate, Gorgon (East), Mumbai - 400063 Email: <a href="mailto:camg99@gmail.com">camg99@gmail.com</a> & <a href="mailto:corp.mumbai@gmail.com">corp.mumbai@gmail.com</a>
21	Address and e-mail to be used for correspondence with the resolution professional	<b>MAHESH KUMAR GUPTA</b> C/O KEMCO & Associates, Office at 202, New Heera Parva Industrial Estate, Near Vignesh Industrial Estate, Gorgon (East), Mumbai - 400063 Email: <a href="mailto:camg99@gmail.com">camg99@gmail.com</a> & <a href="mailto:corp.mumbai@gmail.com">corp.mumbai@gmail.com</a>
22	Forms to be submitted by or with	Website can be sought by emailing at <a href="mailto:camg99@gmail.com">camg99@gmail.com</a> & <a href="mailto:corp.mumbai@gmail.com">corp.mumbai@gmail.com</a>
23	Date of publication of Form G	22/01/2022

**MAHESH KUMAR GUPTA**  
 RESOLUTION PROFESSIONAL  
 OF INDIRA INDUSTRIES LIMITED  
 Registered Address: 202, New Heera Parva Industrial Estate, Near Vignesh Industrial Estate, Gorgon (East), Mumbai - 400063

**VAISHALI PHARMA LTD.**  
 CIN: L2310MH0000PLC181832  
 Corp. & Reg. Office: 706/707, 7<sup>th</sup> Floor, Anant Business Centre, R.C. Patel Road, Off. Sodekhane Lane, Borivli (West), Mumbai - 400092 | Tel.: +91-22-42171819 | E-mail: [investor@vaishalipharma.com](mailto:investor@vaishalipharma.com)

**EXTRACT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021** (₹ in Lakhs)

Sl. No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Nine Months ended	Nine Months ended	Year ended
		31-Dec-21 (Unaudited)	30-Sep-21 (Unaudited)	31-Dec-20 (Unaudited)	30-Sep-21 (Unaudited)	31-Dec-20 (Unaudited)	31-Mar-21 (Audited)
1	Income from Operations	2,228.18	1,996.14	2,129.63	5,041.59	3,483.23	5,377.30
2	Net Profit before Tax, Exceptional Items	214.31	186.86	232.64	509.43	337.13	140.45
3	Net Profit before tax after Exceptional Items	214.31	186.86	232.64	509.43	337.13	140.45
4	Net Profit after tax, Exceptional Items	160.72	140.15	172.15	382.08	249.48	194.23
5	Total Comprehensive Income	160.72	140.15	172.15	382.08	249.48	194.23
6	Equity Share Capital	1,054.62	1,054.62	1,054.62	1,054.62	1,054.62	1,054.62
7	Earnings Per Share						
1	Basic	1.52	1.33	1.63	3.62	2.37	0.99
2	Diluted	1.52	1.33	1.63	3.62	2.37	0.99

NOTE - 1: The above is an extract of the detailed format of the Un-audited Financial Results for the Quarter and nine months ended December 31, 2021 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The Detailed format of the Un-audited Financial Results are available on the Stock Exchange Websites - [www.nseindia.com](http://www.nseindia.com) and on the Company Website - [www.vaishalipharma.com](http://www.vaishalipharma.com)  
 2: The above results were reviewed by the Audit Committee, and approved by the Board of Directors at their respective meetings held on January 21, 2022. Statutory auditors have carried out their review of the above results.  
 By order of the Board  
 Vaishali Pharma Limited  
 Sd/-  
 Alul Vaasal  
 Chairman & Managing Director  
 Place: Mumbai  
 Date: January 21, 2022

**ICICI Prudential Asset Management Company Limited**  
 Corporate Identity Number: U99999DD1993PLC054135

Registered Office: 12<sup>th</sup> Floor, Narain Manzil, 23, Barakhamba Road, New Delhi - 110 001.  
 Corporate Office: One BKC, 13<sup>th</sup> Floor, Bandra Kurla Complex, Mumbai - 400 051.  
 Tel.: +91 22 2652 5000, Fax: +91 22 2652 8100, Website: [www.icicirpfm.com](http://www.icicirpfm.com),  
 Email id: [enquiry@icicirpfm.com](mailto:enquiry@icicirpfm.com)

Central Service Office: 2<sup>nd</sup> Floor, Block B-2, Nirlon Knowledge Park, Western Express Highway, Goregaon (E), Mumbai - 400 063. Tel.: 022 2685 2000 Fax: 022 26886313

**Notice to the Investors/Unit holders of ICICI Prudential Medium Term Bond Fund and ICICI Prudential Quant Fund (The Schemes)**  
 Notice is hereby given that ICICI Prudential Trust Limited, Trustee to ICICI Prudential Mutual Fund has approved the following distribution under Income Distribution cum capital withdrawal option (IDCW option) of the Schemes, subject to availability of distributable surplus on the record date i.e. on January 27, 2022:-

Name of the Schemes/Plans	Quantum of IDCW (₹ per unit) (Face value of ₹ 10/- each) <sup>5P</sup>	NAV as on January 20, 2022 (₹ Per unit)
<b>ICICI Prudential Medium Term Bond Fund</b>		
Quarterly IDCW	0.0487	10.5463
Direct Plan - Quarterly IDCW	0.0699	11,1066
<b>ICICI Prudential Quant Fund</b>		
IDCW	1.30	14.53
Direct Plan - IDCW	1.30	14.65

5 The distribution will be subject to the availability of distributable surplus and may be lower depending upon the extent of distributable surplus available on the record date under the IDCW option of the Schemes.  
 # Subject to deduction of applicable statutory levy, if any  
 \* or the immediately following Business Day, if that day is a Non-Business Day.  
 The distribution with respect to IDCW will be done to all the unit holders/beneficial owners whose names appear in the register of unit holders/Statement of beneficial owners maintained by the Depositories, as applicable under the IDCW option of the Schemes, at the close of business hours on the record date.

It should be noted that pursuant to payment of IDCW, the NAV of the IDCW option of the Schemes would fall to the extent of payout and statutory levy (if applicable).

**For ICICI Prudential Asset Management Company Limited**  
 Place: Mumbai  
 Date: January 21, 2022  
 Sd/-  
 Authorised Signatory  
 No. 009/01/2022

To know more, call 1800 222 999/1800 200 6666 or visit [www.icicirpfm.com](http://www.icicirpfm.com)  
 As part of the Go Green Initiative, investors are encouraged to register/update their e-mail id and mobile number to support paper-less communications.  
 To increase awareness about Mutual Funds, we regularly conduct Investor Awareness Programs across the country. To know more about it, please visit <https://www.icicirpfm.com> or visit AMFI's website <https://www.amfiindia.com>  
 Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

**IDBI BANK**  
 IDBI BANK LIMITED  
 CIN: L65100MH2004G0148838  
 Regd. Office: IDBI Tower, WTC Complex, Cuffe Parade, Mumbai - 400 005  
 Tel.: (022) 66582711, 66653336, website: [www.idbibank.in](http://www.idbibank.in), email id: [info@idbi.com](mailto:info@idbi.com)

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021** (₹ in crore)

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter ended 31-12-2021 (Unaudited)	Quarter ended 31-12-2020 (Unaudited)	Year ended 31-03-2021 (Audited)	Quarter ended 31-12-2021 (Unaudited)	Quarter ended 31-03-2021 (Unaudited)	Year ended 31-03-2021 (Audited)
1	Total Income from Operations (net)	5772.86	6003.91	24501.24	5838.73	6959.51	24747.95
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	965.84	842.95	2368.62	996.93	869.92	2484.41
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary Items)	965.84	842.95	2368.62	996.93	869.92	2484.41
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary Items)	578.25	378.42	1359.46	612.34	303.15	1513.97
5	Equity Share Capital	10752.40	10752.40	10752.40	10752.40	10752.40	10752.40
6	Reserves (including Revaluation Reserve as shown in the Audited Balance Sheet of the previous year)	19777.22	17140.41	19777.22	20594.19	17961.76	20594.19
7	Securities Premium Account	50719.75	50718.27	50719.75	50719.70	50718.27	50732.28
8	Net Worth (including Revaluation Reserve & Intangible Assets)	18523.64	15168.20	15850.92	19664.99	15976.16	16755.32
9	Paid up Debt Capital/ Outstanding Debt	16290.75	30648.76	15908.05	16290.75	30646.76	15908.05
10	Outstanding Redeemable Preference Shares	-	-	-	-	-	-
11	Debt Equity Ratio (excluding revaluation reserve & intangible assets)	0.88	2.02	1.00	0.83	1.92	0.95
12	Earnings Per Share (₹ 10/- each) in ₹ (for continuing and discontinued operations before & after extraordinary items) (not annualised)						
(i)	Basic	0.54	0.36	1.30	0.57	0.38	1.44
(ii)	Diluted	0.54	0.36	1.30	0.57	0.38	1.44
13	Capital Redemption Reserve	-	-	-	-	-	-
14	Debtturn Redemption Reserve	-	-	-	-	-	-

Notes:  
 1. The above is an extract of the detailed format of Quarterly / Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Yearly Financial Results are available on the websites of the Stock Exchange (s) and the related entity ([www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com) and [www.idbibank.in](http://www.idbibank.in)).  
 2. For the other line items referred in Regulation 32 (4) of the LODR Regulations, pertinent disclosures have been made to the Stock Exchange (s) (NSE & BSE) and can be accessed on the URL ([www.resendia.com](http://www.resendia.com), [www.bseindia.com](http://www.bseindia.com) and [www.idbibank.in](http://www.idbibank.in)).  
 3. Information relating to Total Comprehensive Income and Other Comprehensive Income are not furnished as Ind AS is not yet made applicable to banks.  
 By order of the Board  
 Place: Mumbai  
 Date: January 21, 2022  
 (Suresh Khatanhar) (J. Samuel Joseph) (Rakesh Sharma)  
 Deputy Managing Director Deputy Managing Director Managing Director & CEO  
 Hyderabad  
 January 21, 2022

**GLAND PHARMA LIMITED**  
 Corporate Identification Number: L24239TG978PLC02276  
 Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma 'X' Roads, D.P. Pally, Dundigudi - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India  
 Tel.: +91 84556 99999; Website: [www.glandpharma.com](http://www.glandpharma.com); E-mail: [investors@glandpharma.com](mailto:investors@glandpharma.com)

**EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021** (₹ in Millions)

Particulars	Quarter ended			Nine months ended		
	31-Dec-21 (Unaudited)	30-Sep-21 (Unaudited)	31-Dec-20 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-20 (Unaudited)	Year ended 31-Mar-21 (Audited)
Revenue from operations	10,633.25	10,804.69	8,594.19	32,976.94	25,751.28	54,628.76
Profit before tax	3,659.63	4,006.65	2,732.38	12,380.68	9,658.67	13,348.90
Profit for the period/year	2,739.22	3,021.20	2,041.07	9,257.62	7,355.54	9,969.63
Total comprehensive income (after taxes)	2,739.22	3,021.20	2,041.07	9,257.62	7,355.54	9,969.63
Paid up equity share capital (Face value of ₹/- each)	164.30	164.23	163.28	164.30	163.28	163.59
Other equity	-	-	-	-	-	58,868.83
Earnings per equity share (Face value of ₹/- each): (Not annualised for the quarter and nine months period)						
Basic (₹)	16.62	18.37	12.83	56.41	47.12	63.07
Diluted (₹)	16.62	18.37	12.82	56.41	47.10	62.99

**Additional information on Standalone Financial Results is as follows:** (₹ in Millions)

Particulars	Quarter ended			Nine months ended		
	31-Dec-21 (Unaudited)	30-Sep-21 (Unaudited)	31-Dec-20 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-20 (Unaudited)	Year ended 31-Mar-21 (Audited)
Revenue from operations	10,633.25	10,804.69	8,594.19	32,976.94	25,751.28	54,628.76
Profit before tax	3,659.63	4,006.65	2,732.38	12,380.68	9,658.67	13,348.92
Profit for the period/year	2,739.22	3,021.20	2,041.07	9,257.62	7,355.54	9,970.05

Notes:  
 1. The Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021 (Unaudited Consolidated Financial Results) of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 21, 2022.  
 2. The public issue net proceeds of the Initial Public Offer are being utilised as per the objects stated in the Prospectus of the Company. Accordingly we don't have any deviations or variations to be reported in the utilisation of the public issue proceeds for the quarter ended December 31, 2021.  
 3. The above is an extract of the detailed format of quarter and nine months ended Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Company's website ([www.glandpharma.com](http://www.glandpharma.com)) and on the website of the National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and BSE Limited ([www.bseindia.com](http://www.bseindia.com)).  
 For and on behalf of the Board  
 Gland Pharma Limited  
 Sd/-  
 Srinivas Sado  
 Managing Director and CEO  
 DIN No. 06900

